Teva Pharmaceutical has bought a 51% stake in data analysis player Immuneering. The deal buys Teva the exclusive use of Immuneering's analytics tools in R&D projects involving treatments for CNS diseases.
After being in business for 18 years and growing its headcount toward 700, Saama Technologies has decided now is the time to do a Series A round. The analytics specialist has raised $35 million from Carrick Capital Partners to bankroll development of industry-specific tools for life sciences and other sectors.
BioXcel has added another big name to its list of clients. Takeda is the latest company to sign up to work with BioXcel, a database-driven drug discovery shop that already boasts relationships with Alexion, Sanofi, Teva and Vertex.
When the FDA laid out its strategic priorities for 2011 to 2015, the agency listed the modernization of its IT infrastructure as a primary objective. Since then, the FDA has seen another chief information officer pass through its revolving doors and faced criticism from the Government Accountability Office, but is still plugging away with the IT modernization agenda in its next strategic plan.
Having invested in data analytics platforms in recent years, pharma R&D labs are working to develop the drugs that will justify their spending. But the experience of Merck suggests the costs can be spread across the business, with manufacturing teams finding the data analytics tools as useful as their peers in R&D do.
Eli Lilly and Humana have teamed up to analyze various data sets to understand disease outcomes, starting with Type 2 diabetes, the companies announced this morning.
BT and Accelrys have expanded their joint efforts to give life sciences researchers access to web-based software tools and data. The companies have combined their respective technologies again to help researchers mine massive data sets from U.K. and U.S. sources for valuable knowledge.
While Big Data is a real problem, it's not a Big Problem. What is a Big Problem, on the other hand, is the challenge of dealing with the diverse variety of (small) data that's needed for decision-making throughout the drug discovery, development, and commercialization life cycles.
The move gives the consulting giant the keys to Newton, MA-based Recombinant Data's growing business that serves the data needs of hospitals, research institutions and healthcare companies.
The Pittsburgh-based health group has tapped Oracle, IBM, Informatica and dbMotion for technology in the $100 million project, which will give clinicians, researchers, administrators and others real-time access to data and analytics, UPMC announced Oct. 1.